ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.15
(53.85%)
USD 0.15
(53.85%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 409.42 Thousand USD | -46.75% |
| 2022 | 768.8 Thousand USD | -53.86% |
| 2021 | 1.66 Million USD | 524.77% |
| 2020 | 266.7 Thousand USD | 0.0% |
| 2017 | 7 Million USD | -58.5% |
| 2016 | 16.88 Million USD | -43.85% |
| 2015 | 30.08 Million USD | 19.48% |
| 2014 | 25.17 Million USD | -13.0% |
| 2013 | 28.94 Million USD | 7.11% |
| 2012 | 27.01 Million USD | 277.85% |
| 2011 | 7.15 Million USD | 33.28% |
| 2010 | 5.36 Million USD | 264.3% |
| 2009 | 1.47 Million USD | -52.92% |
| 2008 | 3.12 Million USD | -38.3% |
| 2007 | 5.07 Million USD | 373.95% |
| 2006 | 1.06 Million USD | -23.54% |
| 2005 | 1.39 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | 409.42 Thousand USD | -46.75% |
| 2022 FY | 768.8 Thousand USD | -53.86% |
| 2022 Q4 | 768.8 Thousand USD | 7.62% |
| 2022 Q3 | 714.36 Thousand USD | 0.0% |
| 2022 Q1 | 1.1 Million USD | -33.83% |
| 2021 FY | 1.66 Million USD | 524.77% |
| 2021 Q3 | 14.7 Thousand USD | 0.0% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q4 | 1.66 Million USD | 11233.8% |
| 2020 Q4 | 266.7 Thousand USD | 0.0% |
| 2020 FY | 266.7 Thousand USD | 0.0% |
| 2018 Q2 | 3.82 Million USD | -25.85% |
| 2018 Q1 | 5.16 Million USD | -26.32% |
| 2017 Q2 | 4.81 Million USD | -54.21% |
| 2017 Q4 | 7 Million USD | 3.45% |
| 2017 FY | 7 Million USD | -58.5% |
| 2017 Q3 | 6.77 Million USD | 40.85% |
| 2017 Q1 | 10.5 Million USD | -37.79% |
| 2016 Q4 | 16.88 Million USD | -24.02% |
| 2016 Q3 | 22.22 Million USD | 15.38% |
| 2016 Q1 | 24.69 Million USD | -17.92% |
| 2016 Q2 | 19.26 Million USD | -21.98% |
| 2016 FY | 16.88 Million USD | -43.85% |
| 2015 Q2 | 33.15 Million USD | -10.34% |
| 2015 FY | 30.08 Million USD | 19.48% |
| 2015 Q4 | 30.08 Million USD | -2.49% |
| 2015 Q1 | 36.97 Million USD | 46.86% |
| 2015 Q3 | 30.85 Million USD | -6.95% |
| 2014 Q4 | 25.17 Million USD | -0.78% |
| 2014 Q3 | 25.37 Million USD | -6.49% |
| 2014 Q2 | 27.13 Million USD | 3.25% |
| 2014 Q1 | 26.28 Million USD | -9.18% |
| 2014 FY | 25.17 Million USD | -13.0% |
| 2013 Q2 | 26.18 Million USD | 4.43% |
| 2013 FY | 28.94 Million USD | 7.11% |
| 2013 Q4 | 28.94 Million USD | -3.33% |
| 2013 Q3 | 29.93 Million USD | 14.35% |
| 2013 Q1 | 25.07 Million USD | -7.21% |
| 2012 Q3 | 10.69 Million USD | -11.36% |
| 2012 Q1 | 14.41 Million USD | 101.61% |
| 2012 Q2 | 12.06 Million USD | -16.31% |
| 2012 FY | 27.01 Million USD | 277.85% |
| 2012 Q4 | 27.01 Million USD | 152.67% |
| 2011 FY | 7.15 Million USD | 33.28% |
| 2011 Q1 | 11.37 Million USD | 111.93% |
| 2011 Q2 | 10.23 Million USD | -9.95% |
| 2011 Q3 | 8.88 Million USD | -13.19% |
| 2011 Q4 | 7.15 Million USD | -19.55% |
| 2010 Q1 | 2.73 Million USD | 85.38% |
| 2010 Q3 | 6.36 Million USD | -19.14% |
| 2010 Q2 | 7.87 Million USD | 188.52% |
| 2010 Q4 | 5.36 Million USD | -15.77% |
| 2010 FY | 5.36 Million USD | 264.3% |
| 2009 Q1 | 2.63 Million USD | -15.66% |
| 2009 Q3 | 2.03 Million USD | -18.21% |
| 2009 FY | 1.47 Million USD | -52.92% |
| 2009 Q4 | 1.47 Million USD | -27.6% |
| 2009 Q2 | 2.48 Million USD | -5.74% |
| 2008 Q2 | 4.07 Million USD | -10.55% |
| 2008 FY | 3.12 Million USD | -38.3% |
| 2008 Q4 | 3.12 Million USD | -12.99% |
| 2008 Q1 | 4.55 Million USD | -10.09% |
| 2008 Q3 | 3.59 Million USD | -11.84% |
| 2007 FY | 5.07 Million USD | 373.95% |
| 2007 Q4 | 5.07 Million USD | -6.18% |
| 2007 Q3 | 5.4 Million USD | -2.06% |
| 2007 Q1 | 3.01 Million USD | 181.57% |
| 2007 Q2 | 5.51 Million USD | 83.18% |
| 2006 Q2 | 1.26 Million USD | -9.26% |
| 2006 FY | 1.06 Million USD | -23.54% |
| 2006 Q4 | 1.06 Million USD | -5.92% |
| 2006 Q3 | 1.13 Million USD | -9.81% |
| 2006 Q1 | 1.38 Million USD | 0.0% |
| 2005 FY | 1.39 Million USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -17623.896% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 79.092% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 96.121% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 25.845% |
| Rebus Holdings, Inc. | 5000.00 USD | -8088.44% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.686% |
| Qrons Inc. | 420.00 USD | -97381.429% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 46.873% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.535% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 14.803% |
| Skye Bioscience, Inc. | 11.94 Million USD | 96.571% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.946% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 94.329% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -436.216% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.618% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 71.41% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -465.774% |
| Mesoblast Limited | 667.9 Million USD | 99.939% |
| Marizyme, Inc. | 22.01 Million USD | 98.14% |
| Genus plc | 1.02 Billion USD | 99.96% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 69.859% |
| Pharming Group N.V. | 462.85 Million USD | 99.912% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 87.642% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 17.958% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 34.701% |
| ContraFect Corporation | 20.67 Million USD | 98.02% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -4.882% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -7.129% |
| IMV Inc. | 31.33 Million USD | 98.693% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 90.125% |
| MultiCell Technologies, Inc. | 126.22 USD | -324271.732% |
| ONE Bio Corp. | 70.08 Million USD | 99.416% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 56.43% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.681% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 5.164% |
| Q BioMed Inc. | 3.51 Million USD | 88.354% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.836% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -56.7% |
| Biomind Labs Inc. | 73.81 Thousand USD | -454.63% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.908% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 71.741% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.636% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 85.092% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 40.446% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 84.272% |
| GB Sciences, Inc. | 103.44 Thousand USD | -295.799% |
| Alpha Cognition Inc. | 2.45 Million USD | 83.304% |
| HST Global, Inc. | 1526.00 USD | -26729.751% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 58.559% |
| Halberd Corporation | 10.13 Thousand USD | -3941.279% |
| Enzolytics Inc. | 361.7 Million USD | 99.887% |
| Agentix Corp. | 261.39 Thousand USD | -56.631% |
| Resverlogix Corp. | 8.11 Million USD | 94.955% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 78.198% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.991% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.142% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 35.993% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1697.208% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 95.425% |
| AVAX Technologies, Inc. | 7.37 Million USD | 94.45% |
| Zenith Capital Corp. | 7410.00 USD | -5425.263% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.988% |
| Ember Therapeutics, Inc. | 184.00 USD | -222411.957% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -27.226% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -56.648% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 55.879% |
| Kadimastem Ltd | 2.3 Million USD | 82.231% |
| Helix BioMedix, Inc. | 3.02 Million USD | 86.466% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.223% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.188% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -617.102% |
| LadRx Corporation | 2.3 Million USD | 82.26% |
| Cell Source, Inc. | 195.17 Thousand USD | -109.776% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -15.781% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -15.781% |
| NovAccess Global Inc. | 62.24 Thousand USD | -557.727% |
| Affymax, Inc. | 7.44 Million USD | 94.499% |
| Itoco Inc. | 1.4 Million USD | 70.757% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -328.01% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -286.247% |
| Mobile Lads Corp. | 52.00 USD | -787250.0% |
| CytoDyn Inc. | 11.13 Million USD | 96.323% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -186.365% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2189.832% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -6.213% |
| SYBLEU INC | 330.46 Thousand USD | -23.892% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| International Stem Cell Corporation | 5.39 Million USD | 92.404% |
| Bioxytran, Inc. | 137.63 Thousand USD | -197.463% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.271% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.53% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -418.256% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 52.65% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 94.553% |
| Neutra Corp. | 2851.00 USD | -14260.645% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.737% |
| PureTech Health plc | 693.97 Million USD | 99.941% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 94.927% |
| IXICO plc | 15.84 Million USD | 97.416% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 95.056% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.604% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.877% |